Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership 
Air Canada Express Plane Collides with Ground Vehicle at LaGuardia Airport 
Palantir's Maven AI Earns Pentagon "Program of Record" Status, Reshaping Military AI Strategy 
Virgin Australia Adjusts Fares Amid Rising Aviation Costs and Middle East Tensions 
Goldman Sachs Delays Bank of England Rate Cut Forecast Amid Middle East Inflation Risks 
FEMSA Cuts Jobs at Spin Fintech Unit, Refocuses Strategy on Oxxo Stores 
Judge Dismisses Sam Altman Sexual Abuse Lawsuit, But Sister Can Refile 
US-Iran War: Trump Eyes Military Exit as Markets React to Potential De-escalation 
South Korean Stocks Tumble as Hawkish BOK Governor Appointment Rattles Markets 
Qatar's Economy Under Pressure: How Regional Conflict Could Reshape Global Investment in 2026 
Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
Iran War Fears Send Oil Prices Surging as U.S. Weighs Ground Troop Deployment 
J.P. Morgan Now Expects Two ECB Rate Hikes Amid Inflation Pressures 
Tesla Eyes $2.9 Billion in Chinese Solar Equipment to Power 100 GW U.S. Manufacturing Push 
EA's $15B Debt Offering Draws $25B in Investor Demand Amid Credit Market Turmoil 
Elliott Investment Management Takes Multibillion-Dollar Stake in Synopsys 
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
Abbott Nutrition said last weekend that it had reopened its Sturgis, Michigan plant to resume the production of baby formula. The company hopes that the nationwide shortage of milk will be addressed once it begins the normal production once again.
Abbott Nutrition was able to open its production facility in Michigan after the U.S. Food and Drug Administration (USFDA) had given it the go-ahead to do so. The permit was granted by the agency after the company met the initial requirements as part of a May 16 consent decree.
According to CNBC, Abbott Nutrition will now restart the production of its EleCare baby formula that has been formulated for children who have difficulties digesting other products. The company will also manufacture its other specialty milk and metabolic formulas for infants.
As the company is now able to begin production again, it is hoping to release the first batch of EleCare milk products by June 20. Currently, Abbott is still working to comply with the guidelines set for the resumption of production for its Similac milk line and other infant formulas.
“We understand the urgent need for formula and our top priority is getting high-quality, safe formula into the hands of families across America,” Abbott’s spokesman said in a statement. “We will ramp production as quickly as we can while meeting all requirements.“
It was noted that the issue with the supply of baby formula began in the early stage of the COVID-19 pandemic. However, the situation got worse when Abbott Nutrition’s production facility in Michigan was ordered to close due to contamination. The plant was shut down in February following reports of illnesses in babies after consuming the company-made milk formulas, and two infants have died.
“The FDA is continuing to work diligently to ensure the safe resumption of production of infant formula at Abbott Nutrition’s Sturgis, Michigan, facility,” the USFDA commented with regards to Abbot’s plant reopening. “The agency expects that the measures and steps it is taking, and the potential for Abbott Nutrition’s Sturgis, Michigan, facility, to safely resume production in the near-term, will mean more and more infant formula is either on the way to or already on store shelves moving forward.”
